April 2021 - Cancer Currents Blog
-
Study Details Long-Term Side Effects of Immune Checkpoint InhibitorsWhile doctors are familiar with the short-term side effects of immune checkpoint inhibitors, less is known about potential long-term side effects. A new study details the chronic side effects of these drugs in people who received them as part of treatment for melanoma.
-
Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal MelanomaIn a large trial, tebentafusp helped patients with uveal melanoma live longer than patients who received other treatments for the disease. Uveal melanoma is an aggressive cancer of the eye, and many patients do not survive for a year once it has spread.
-
Can Acupuncture Help Cancer Survivors with Chronic Pain?In a large clinical trial, cancer survivors treated with acupuncture had modest improvements in chronic pain compared with those who received standard pain treatments. The study couldn’t rule out a placebo effect for the improvement with acupuncture.
-
NF1 Associated with More Cancer Types Than Previously KnownThe study also found that people with neurofibromatosis type 1 (NF1) developed some cancers at an earlier age and were more likely to die from several cancer types, which make preventive measures and early diagnosis important for people with NF1.
-
FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple MyelomaThe Food and Drug Administration has approved idecabtagene vicleucel (Abecma) for some people with multiple myeloma. The approval is based, in part, on a small study in which ide-cel partially or completely shrank tumors in 72% of patients.
-
Whole-Genome Sequencing Could Help Guide AML TreatmentFor people with acute myeloid leukemia and related cancers, a new study shows whole-genome sequencing could replace a series of conventional tests used to help guide decisions about treatment.
-
Researchers Create Modified Antibodies to Target RAS and p53 in CancerResearchers have developed synthetic antibodies, called diabodies, that block the activity of two of the most notorious cancer-related proteins, RAS and p53. In experiments in mice, the synthetic antibodies shrank tumors with these mutated proteins.
-
Blinatumomab Improves Survival in Children with Relapsed LeukemiaThe results of two trials establish blinatumomab (Blincyto) as a new standard treatment for children and young adults with high-risk relapsed B-cell acute lymphoblastic leukemia after remission has been achieved and before a stem cell transplant.